Scroll for more
news Apr 25, 2017

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Using our unique AI, researchers can make connections that they would have previously found impossible given the shear amount of data available in the sciences. Ken goes onto explain what makes our offering and business model unique and where this differs from DeepMind. He also urges British start-ups to stop selling out early, stressing the real opportunity for the UK to lead in this sector.  

Read full article here